Business
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage
About this update from Sensei Biotherapeutics, Inc.
[{"type":"image","alt":"Sensei Biotherapeutics","displaySize":"","headline":null,"caption":"Sensei Biotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":111,"url":"https://media.zenfs.com/en/globenewswire.com/0bb46371fbe8afb08b27525aefb81405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tSVB9mWPe6cbY7LRif6RFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0bb46371fbe8afb08b27525aefb81405","width":300,"height":111}},"lazy":false},{"type":"text","content":"- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population -","length":163,"tagName":"p"},{"type":"text","content":"- Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - ","length":90,"tagName":"p"},{"type":"text","content":"- Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 -","length":92,"tagName":"p"},{"type":"text","content":"- Cash runway into the second quarter of 2026 -","length":47,"tagName":"p"},{"type":"text","content":"BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2024, and provided corporate updates.","length":309,"tagName":"p"},{"type":"text","content":"“2024 was a pivotal year for Sensei, as we advanced solnerstotug through dose expansion and began to demonstrate its clinical potential in patients who have progressed on and are resistant to PD-(L)1 therapy” said John Celebi, President and CEO of Sensei Bio. “The responses we’ve observed in PD-(L)1 resistant tumors are highly encouraging and we believe support solnerstotug’s differentiated approach to targeting VISTA. In the context of available data across checkpoint inhibitor regimens, solnerstotug stands out for its encouraging response rates and favorable tolerability profile in PD-(L)1 resistant tumors, a setting with limited treatment options and no approved therapies targeting VISTA. We are now focused on completing dose expansion for patients on study and finalizing a robust Phase 2 strategy.”","length":813,"tagName":"p"},{"type":"tex...